Luminance Health has been awarded #1 place in the Best Workplaces™ Switzerland in its category in the Award Ceremony held on 21 May 2026 by Great Place To Work® (GPTW). This award reflects Luminance Health’s continued commitment to fostering a purpose-driven, high-performing workplace culture.

Luminance Health proudly celebrates its first anniversary, marking a year defined by significant expansion, meaningful partnerships, and a steadfast commitment to elevating quality and innovation across the life sciences sector.

Luminance Health AG today announced a strategic partnership with Advyzom LLC, a Danforth Health company, to deliver transatlantic regulatory expertise for life science companies.

Luminance Health is proud to be Certified™ by Great Place To Work®, a milestone that reflects the strong culture and team spirit built across the organization. This prestigious recognition is based entirely on direct employee feedback about their experience working at Luminance Health.

As we enter 2026, Luminance extends its sincere appreciation to all clients and partners for their continued trust. Your collaboration enables us to support you in navigating complex regulatory, quality, and market environments with precision and purpose, delivering clarity, compliance, and strategic advantage across an increasingly competitive life science landscape.

Luminance Health is proud to announce that our CEO, Shayesteh Fürst-Ladani, has been elected President of POWHER – Female Entrepreneurs Basel, a dynamic community of volunteers dedicated to building networks, celebrating female entrepreneurship, and driving systemic change in the Basel region.

Ilmac hosted a powerful panel discussion under the banner Women in Life Science, spotlighting the voices and vision of women shaping the future of healthcare. Among the distinguished speakers were Shayesteh Fürst-Ladani, CEO of Luminance Health, and Joanna Hanley, Head of Quality Assurance, whose contributions underscored the urgency of advancing gender equity in life sciences.

Luminance Health was proud to sponsor the Medtech & Pharma Platform Association Annual Conference 2025, held at the Novartis Campus in Basel. This leading European event brought together experts from medtech, pharma, diagnostics, and digital health to shape the future of combined products, where medicines, devices, and digital technologies converge for a medical purpose.

Luminance conducted a tailored webinar for life science professionals in Asia and North America preparing to launch pharmaceutical products in the European Union. The event provided a focused yet thorough exploration of the essential requirements for a successful market entry, equipping attendees with actionable insights and strategic guidance.

At this year’s BioValley Annual Event, Luminance Health was represented by CEO Shayesteh Fürst-Ladani and Adrian Sutter, Associate Director Public Affairs. The event featured a high-level roundtable titled “Pharma Company Strategy in a Changing Geopolitical Environment”.

Anastasia Agapouda, Senior Manager Quality Assurance & Pharmacovigilance, and Jack Cronk, Senior Manager Medical Affairs, represented Luminance Health at the “Talk & Connect 2025” event hosted by the Basel Area.

We are proud to share that our CEO, Shayesteh Fürst-Ladani, was a featured speaker at the recent British-Swiss Chamber of Commerce (BSCC) event, “Resourceful Board Governance in the AI Transformation – Unlock the Future of Corporate Governance in the Age of AI.”

Our CEO, Shayesteh Fürst-Ladani, and Project Finance Manager, Katrin Grenda, took part in the inaugural event of the Pharma Women’s Network, a newly launched series dedicated to connecting and empowering women in the pharmaceutical and life sciences industries.

We were delighted to take part in the 8th Swiss-Chinese Life Sciences Forum, an inspiring event bringing together biotech, pharma, and investment leaders committed to shaping the future of healthcare innovation between Switzerland and China.

Our Swissmedic license is the cornerstone of our commitment to the highest standards of Good Practice (GxP). Supported by a fully implemented Quality Management System that meets Swissmedic’s requirements, we ensure every stage is rigorously documented, controlled and subject to continuous review.

As a certified Small and Medium-sized Enterprise (SME) under European Medicines Agency criteria, we specialize in navigating non-EU clients through the EMA submission process. By combining bespoke guidance with deep EMA expertise, we empower innovators outside the EU to deliver vital therapies to European patients more swiftly and cost-effectively.

Jane Müller, Head of Legal & HR, took part in the BaseLaunch event, which centered on collaborative strategies for early-stage innovation. The program highlighted approaches to building strong partnerships in the biotech space and concluded with a networking apéro to encourage dialogue and knowledge sharing.

At Future Labs Live, Shayesteh Fürst-Ladani, CEO, and Jack Cronk, Senior Manager Medical Affairs, attended the keynote panel titled Transforming Research: Can We Make Open Science a Reality?, contributing to conversations on transparency, collaboration, and open innovation in AI-driven research.

Sabrina Urwyler, Associate Director Regulatory Affairs & Project Management, attended the Life Science Zurich Impact Conference on “Precision Medicine and AI Innovations,” where experts from academia, healthcare, and research gathered to explore the transformative role of artificial intelligence in medical treatment. Discussions addressed both the potential and the challenges of these technologies in advancing translational medicine.

The Advisory Board comprises senior executives and subject-matter experts with extensive experience across pharmaceuticals, biotechnology, medical technology, and global regulatory agencies. Their collective expertise will enhance Luminance Health’s ability to support clients – ranging from early-stage ventures to multinational enterprises and non-profit institutions – through each phase of the innovation lifecycle, from research and development to commercialization.